Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

MaxCyte, Inc. (MXCT) Stock · SELL · CRISIS | LOPJLB

MaxCyte, Inc. (MXCT)

Healthcare · Biotechnology · NASDAQ · US

$1.02-1.92%Close

SELLCRISIS · day 6

MXCT▼ SELL

$1.02-1.92%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $109M
Beta: 1.53
P/E (TTM): -3.26

Short % float: 1.20%
Days to cover: 2.8
SI change: -10.1%

1W: -6.42%
1M: -16.39%

vs SPY 1W: -7.98%
vs SPY 1M: -18.16%

Industry peers

FMP comparable companies · ranked by market cap

AVRSELLAnteris Technologies Global Corp.$750MCRISISQ 18$7.71-2.79%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a…

Employees: 91
Headquarters: US
Founded: 2021
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 107.1M
Float: 91.1%

maxcyte.com ↗

Key executives

Maher Masoud — President, Chief Executive Officer & Executive Director

Parmeet Ahuja — Chief Financial Officer

Jay Gelfman — Chief Operations Officer

SEC filings

EDGAR · CIK 12870980 · MXCT

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish466.7%

Neutral233.3%

Bearish00.0%

L $6.00Avg $6.00H $6.00

Target$6.00+488.24%

Last$1.02

Company news

globenewswire.com · 16d ago

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

globenewswire.com · 28d ago

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 51d ago

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

marketbeat.com · 58d ago

MaxCyte Q2 Earnings Call Highlights

seekingalpha.com · 58d ago

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

zacks.com · 58d ago

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

globenewswire.com · 58d ago

MaxCyte Reports Second Quarter 2026 Financial Results

globenewswire.com · 80d ago

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

globenewswire.com · 86d ago

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

Market news & ticker search · RSS for MXCT

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE